Skip to content

April 28, 2026

Home
Signal News
Biopharma Brief
Week in Review
Contact

Light/Dark Button

Search for:

Home
Clinical Data
Boehringer/Zealand dual-acting drug causes 16.6% weight loss

Clinical Data

Boehringer/Zealand dual-acting drug causes 16.6% weight loss

Pharmaphorum

Boehringer/Zealand reveal first phase 3 data with dual GLP-1/glucagon weight-loss drug survodutide.

Metabolic & GLP-1

Read full story

pharminent April 28, 2026 (Last updated: April 28, 2026)

Pharmaphorum

Boehringer/Zealand reveal first phase 3 data with dual GLP-1/glucagon weight-loss drug survodutide.

Metabolic & GLP-1

Read full story

Post navigation

Previous: BioMarin acquires Amicus Therapeutics for $4.8bn

Next: Seaport and Hemab target $180m IPOs as biotech listings accumulate

Related Stories

Clinical Data

Boehringer, Zealand’s obesity drug ‘more akin’ to Novo’s Wegovy in Phase 3

pharminent April 28, 2026

Clinical Data

AACR 2026: Combo therapies by Moderna, Marengo show promise in skin, breast cancer

pharminent April 28, 2026

Clinical Data

Oruka surges as long-acting psoriasis drug shows early promise

pharminent April 27, 2026

You May Have Missed

Clinical Data

Boehringer, Zealand’s obesity drug ‘more akin’ to Novo’s Wegovy in Phase 3

pharminent April 28, 2026

Clinical Data

AACR 2026: Combo therapies by Moderna, Marengo show promise in skin, breast cancer

pharminent April 28, 2026

M&A / Deals

Lilly, AI biotech Profluent ink $2.25B pact in search of genetic medicine ‘holy grail’

pharminent April 28, 2026

Regulatory

GSK eyes October FDA verdict on chronic hep B drug

pharminent April 28, 2026

Copyright © 2026 All rights reserved. | ReviewNews by AF themes.